Shigeo Tamiya

Shigeo Tamiya studies cellular and molecular processes in the eye, particularly how retinal pigment epithelial (RPE) cells and Müller cells change into scar-forming cells (a process called myofibroblast transdifferentiation) that contributes to blinding conditions like proliferative vitreoretinopathy and choroidal neovascularization. Much of the work explores signaling pathways (e.g., Rho, TRPV4, FAK/PYK2, telomerase) and tests potential drug treatments, including dasatinib and cannabinoid-related compounds, to prevent or reverse this scarring process. This research is aimed at developing therapies to protect vision after retinal injury or disease.​​

Publication output has been modest and somewhat irregular over the past decade, with a peak in 2017 followed by lower and intermittent yearly counts, averaging about one publication per year over the last five years.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026